Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayMar 01, 2017 2:33 pm

NetworkNewsBreaks – Cinedigm (NASDAQ: CIDM) Partners with The WHAM Network to Launch Global Gaming and eSports Streaming Network

Cinedigm (NASDAQ: CIDM) and The WHAM Network Inc. have entered a partnership to launch The WHAM Network, a 24/7 streaming channel providing news, information and entertainment focused on the global eSports and gaming lifestyle. The network will be operated and marketed by the two companies, and it is expected to launch in the third quarter of 2017. The channel will be available across all major connected mobile devices, gaming consoles, and set top boxes. The companies are currently in talks with additional platforms, skinny bundle providers, and cable operators in order to make the channel broadly available on all modes…

Continue Reading

WednesdayMar 01, 2017 11:50 am

NetworkNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Shares Skyrocket on Innovative Technology Contract from Vizient, Inc. for STREAMWAY® System

Skyline Medical (NASDAQ: SKLN) shares are up 43% after the company announced it has received an Innovative Technology contract from Vizient, Inc. for its FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. Vizient is the largest, member-driven health care performance improvement company in the country with an annual purchasing volume of almost $100 billion. Hospital experts with expertise in this category who serve on one of Vizient’s member-led councils recommended STREAMWAY, which resulted in the contract. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety while improving an organization’s care…

Continue Reading

TuesdayFeb 28, 2017 12:25 pm

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Preclinical Data of NSI-189 Published in Journal of Cellular Physiology

Neuralstem’s (NASDAQ: CUR) preclinical data on NSI-189 was recently published in the Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic plasticity in stroke-induced animals during the 12-week treatment period, which was maintained up to 24 weeks post-stroke. The study demonstrated that in neurologic and motor deficit tests, the animals treated with NSI-189 performed significantly better than the placebo animals. Additionally, the animals treated with NSI-189 continued to improve during the second 12-week period even in the absence of drug treatment. Histological assessment of stroke-induced brains from NSI-189-treated subjects suggest that NSI-189…

Continue Reading

TuesdayFeb 28, 2017 9:35 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Presenting this Morning at the National Investment Banking Association Conference

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its management team will be presenting at the National Investment Banking Association Conference, which is currently underway at the Westin New York Grand Central Hotel in Midtown Manhattan. The company will be presenting alongside the WallStreet Research™ team, who is sponsoring ChineseInvestors.com’s participation at the event. Additionally, WallStreet Research™ has organized, for the CIIX management team, a collection of one-on-one meetings with prospective investors for later in the day at the Penn Club in New York. Interested parties can review ChineseInvestors.com’s presentation materials from the conference by visiting the…

Continue Reading

MondayFeb 27, 2017 12:07 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Reports Positive Data from Phase I Trial of CLR 131 in Multiple Myeloma; Shares Higher

Cellectar Biosciences (NASDAQ: CLRB) this morning issued a positive update of its phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The data show that the 25 mCi/m2 dose was safe and well tolerated, and that adverse events were similar to those in the previous two cohorts. All four cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). While it is premature to report survival-related efficacy data from cohort 3, all patients in cohorts 1 and 2 continue to experience overall survival benefit. …

Continue Reading

MondayFeb 27, 2017 12:04 pm

NetworkNewsBreaks – Pieris Pharmaceuticals (NASDAQ: PIRS) Grants ASKA Pharmaceutical Exclusive Option to License Anemia Drug in Japan

Pieris Pharmaceuticals (NASDAQ: PIRS) this morning announced that it has granted ASKA Pharmaceutical Co., Ltd. an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose phase 2a study in dialysis-dependent anemia patients. Per the agreement, Pieris will immediately receive an option payment of $2.75 million. Following an analysis period after the completion of the planned phase 2a study conducted by Pieris, ASKA may exercise its option to obtain an exclusive license to develop and commercialize PRS-080 in Japan, South Korea and certain other Asian…

Continue Reading

MondayFeb 27, 2017 10:23 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) CEO Presents at Shandong Yibao Biologics Conference

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that CEO Warren Wang recently attended Shandong Yibao Biologics Co. Ltd.’s annual conference, where he was invited to deliver a speech celebrating Yibao Biologics’ 18th anniversary. A modern high-tech enterprise specializing in the research, production and sale of health care products, Yibao Biologics hosts an annual direct sales conference to discuss the development and prospects of Chinese health products enterprises in the United States. “The market for direct selling of natural products in the United States has considerable depth, and varies from the Chinese market in many ways,” Wang stated…

Continue Reading

MondayFeb 27, 2017 9:49 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Scheduled to Present at 29th Annual ROTH Capital Partners Conference

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for eXp Realty LLC, this morning announced that it has been invited to present at the 29th Annual ROTH Capital Partners Conference, which is set to take place from March 12-15, 2017, at the Ritz-Carlton, Laguna Niguel in Dana Point, California. The company’s management team is scheduled to present on Monday, March 13 at 8:00 AM Pacific Time. For those unable to attend, a webcast of the presentation will be made available at http://wsw.com/webcast/roth31/expi. In addition to its presentation, the EXPI team is expected to host one-on-one meetings with prospective investors throughout…

Continue Reading

FridayFeb 24, 2017 11:17 am

NetworkNewsBreaks – Cempra, Inc. (NASDAQ: CEMP) – Phase 3 Study of Fusidic Acid Achieves Primary Endpoint; Shares Rise

Cempra (NASDAQ: CEMP) shares rose 38% following the company’s report of positive topline results from a phase 3 study of oral fusidic acid. The study, which took place in 716 patients with acute bacterial skin and skin structure infections, demonstrated that fusidic acid was well tolerated. Additionally, the study realized the primary endpoint, demonstrating non-inferiority (NI) (10% NI margin) of oral fusidic acid compared to oral linezolid for early clinical response in the intent to treat patient population. The company plans to submit the full data from this study for presentation at an upcoming scientific forum. “We are excited that…

Continue Reading

FridayFeb 24, 2017 11:13 am

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Shares Higher on FDA Approval of Two Strengths of Generic Glucophage® XR

Intellipharmaceutics International (NASDAQ: IPCI) shares were up 27% this morning following news that it has received final approval for its abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths from the U.S. Food and Drug Administration (FDA). Metformin hydrochloride extended release is a generic equivalent for the matching strengths of the branded product Glucophage® XR, which is sold in the United States by Bristol-Myers Squibb and indicated for use in the management of type 2 diabetes. "FDA approval of our application for a generic version of Glucophage® XR provides further…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000